SOD-Expressing Bacillus Composition for Fibrotic Disease Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective drugs to treat fibrotic diseases such as pulmonary fibrosis and hepatic fibrosis, as current treatments are inadequate.
Innovation Solution
A composition comprising a Bacillus sp. strain, a Bacillus sp. strain spore, and/or superoxide dismutase (SOD) is administered to prevent or treat fibrotic diseases, with strains like Bacillus velezensis showing therapeutic effects on pulmonary and hepatic fibrosis, and SOD-overexpressing variants enhancing these effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drugs are used to treat fibrotic diseases, then treatment is provided, but the drugs are ineffective and do not improve fibrosis
Solution Approach 1:
The patent changes the biochemical parameter of antioxidant activity by introducing SOD enzyme expression in Bacillus strains. This enzymatic parameter change directly addresses the oxidative stress condition in fibrotic tissues, converting the ineffective conventional drug approach into an effective biological therapy that restores antioxidant balance and prevents fibrosis progression
Solution Approach 2:
The Bacillus strain acts as a living intermediary that delivers SOD enzyme to the target tissue. This intermediary approach overcomes the limitation of conventional drugs by using a biological vector that can survive, proliferate, and continuously produce the therapeutic enzyme at the disease site, thereby achieving reliable treatment effect
2Reliability
If SOD activity is increased to reduce oxidative stress, then fibrosis is prevented, but the complexity of the treatment increases
Solution Approach 1:
The Bacillus strain is engineered to self-produce and secrete SOD enzyme continuously. This self-service mechanism eliminates the need for repeated external administration of SOD, as the bacterial strain autonomously maintains therapeutic SOD levels in the body, thereby preventing fibrosis while simplifying the treatment regimen
Solution Approach 2:
The patent merges the therapeutic function of SOD enzyme with the biological vehicle of Bacillus strain into a single integrated treatment composition. This combination approach delivers multiple benefits simultaneously: the bacteria provide both the SOD enzyme and their natural probiotic functions, reducing treatment complexity while enhancing fibrosis prevention efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively ameliorates and prevents fibrotic diseases by reducing reactive oxygen species, improving symptoms, and increasing survival rates in animal models, with SOD-overexpressing strains providing superior therapeutic outcomes.
Implementation Method 1
a Bacillus sp. strain, a Bacillus sp. strain spore, and/or a superoxide dismutase (SOD), and a use thereof for preventing, ameliorating, or treating a fibrotic disease
Data Source
AI summary
The present invention relates to a composition for the prevention, alleviation, or treatment of fibrotic diseases, containing a Bacillus species strain, a Bacillus species strain spore, each expressing superoxide dismutase, and/or superoxide dismutase. When orally administered, the composition allows the polypeptide with superoxide dismutase activity to remove reactive oxygen species in vivo, thus being helpful for the prevention, improvement, or treatment of fibrotic diseases such as pulmonary fibrosis or hepatic fibrosis.